source
- Altimmune's GLP-1/glucagon shot reduces drinking in Phase 2 alcohol use disorder trialAltimmune announced results from its mid‑stage Phase 2 RECLAIM trial evaluating pemvidutide, a GLP‑1/glucagon dual agonist, in patients with moderate‑to‑severe alcohol use disorder. The trial comp…
- GSK launches three-year £1.9bn savings plan to boost late-stage R&D and relocate research HQGSK announced a three-year cost-saving programme designed to free cash for its late-stage research and development pipeline while moving its research headquarters. The plan targets annual savings…